Prosthetic Joint Infection

IDSA Prosthetic Joint Infection

IDSA Prosthetic Joint Infection GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/98546

Contents of this Issue

Navigation

Page 8 of 15

ÎÎIndefinite chronic oral antimicrobial suppression with either cephalexin, dicloxacillin, co-trimoxazole, minocycline or doxycycline may follow the above regimen, based on in vitro susceptibility, allergies or intolerances (Table 3) (B-III). ÎÎRifampin alone is NOT recommended for chronic suppression, and rifampin combination therapy is also not generally recommended. ÎÎClinical and laboratory monitoring for efficacy and toxicity is advisable. ÎÎThe decision to offer chronic suppressive therapy must take into account the individual circumstances of the patient including: •  the ability to use rifampin in the initial phase of treatment •  the potential for progressive implant loosening and loss of bone stock •  the hazards of prolonged antibiotic therapy. It is therefore generally reserved for patients who are unsuitable for, or refuse, further exchange revision, excision arthroplasty, or amputation. PJI DUE TO OTHER ORGANISMS ÎÎTreat with 4-6 weeks of pathogen-specific intravenous or highly bioavailable oral antimicrobial therapy (Table 2) (A-II). ÎÎFollow published guidelines for monitoring outpatient IV antimicrobial therapy [Tice AD. op. cit.] (A-II). ÎÎIndefinite chronic oral antimicrobial suppression should follow regimens in Table 3 and be based on in vitro sensitivities, allergies and intolerances (B-III). ▶▶ Chronic suppression after fluoroquinolone treatment of gram-negative bacilli was not unanimously recommended. ▶▶ Clinical and laboratory monitoring for efficacy and toxicity is advisable. ▶▶ Similar considerations regarding hazards and effectiveness apply to the above. After Amputation ÎÎGive pathogen-specific antimicrobial therapy until 24-48 hours after amputation, assuming all infected bone and soft tissue has been surgically removed and there is no concomitant sepsis syndrome or bacteremia. If sepsis syndrome or bacteremia is present, treat according to recommendations for these syndromes (C-III). ÎÎGive 4-6 weeks of pathogen specific intravenous or highly bioavailable oral antimicrobial therapy if, despite surgery, there is residual infected bone and soft tissue (i.e. hip disarticulation for THA infection OR long stem TKA prosthesis where the prosthesis extends above the level of amputation) (Table 2) (C-III). Follow published guidelines for monitoring outpatient IV antimicrobial therapy [Tice AD. op. cit.] (A-II). 7

Articles in this issue

Archives of this issue

view archives of Prosthetic Joint Infection - IDSA Prosthetic Joint Infection